scholarly journals The Effect of Helicobacter pylori Eradication in Patients with Gastroesophageal Reflux Disease: A Meta-Analysis of Randomized Controlled Studies

2020 ◽  
Vol 38 (4) ◽  
pp. 261-268 ◽  
Author(s):  
Yan Zhao ◽  
Yarui Li ◽  
Junbi Hu ◽  
Xin Wang ◽  
Mudan Ren ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Gastroesophageal Reflux Disease ◽  
Gastroesophageal Reflux ◽  
Reflux Disease ◽  
English Literature ◽  
Meta Analysis ◽  
Control Group ◽  
Randomized Controlled ◽  
H Pylori ◽  
Relapse Rates

Aim: Helicobacter pylori infection has been established as a definite risk factor for gastric cancer. However, the consequence of H. pylori eradication on the progression of gastroesophageal reflux disease (GERD) remains controversial. The purpose of our study was to investigate the relationship between H. pylori eradication and the development of GERD. Methods: A comprehensive, English literature search was performed from January 1990 to April 2019. Only randomized controlled trials (RCT) that evaluated the effect of H. pylori eradication on GERD were included. Meta-analysis of pooled OR was performed using Review Manger 5.1.7. Results: Seventeen articles with 6,889 subjects (intention-to-treat) that fulfilled the inclusion criteria were finally included in the analysis. Of them, 8 RCTs have the similar study design and inclusion criterion, which included patients with H. pylori infection but without GERD at baseline. The OR for the development of erosive GERD after H. pylori eradication was 1.67 (95% CI 1.12–2.48, p = 0.01). The OR for the development of GERD-related symptoms after H. pylori eradication in eradication group compared with control group was 1.04 (95% CI 0.84–1.29, p = 0.71). In addition, 9 RCTs included patients with both baseline H. pylori infection and GERD. The OR for the healing rates and relapse rates after H. pylori eradication in the H. pylori eradication group vs. control group was 0.92 (95% CI 0.47–1.82, p = 0.82) and 1.12 (95% CI 0.60–2.09, p = 0.71), respectively. Conclusions: Our meta-analyses showed H. pylori eradication may lead to the development of new erosive GERD. However, eradication of H. pylori may affect neither the healing rates nor relapse rates of preexisting GERD.

scholarly journals Esomeprazole versus omeprazole for the eradication of Helicobacter pylori infection

2018 ◽  
Vol 5 (7) ◽  
pp. 2686
Author(s):  
Rawan Ageeli ◽  
Abdullah Binobaid ◽  
Abdullah Aljadaan ◽  
Mohammed Alhagbani ◽  
Yasser Alotaibi ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Peptic Ulcer ◽  
Gastroesophageal Reflux Disease ◽  
Gastroesophageal Reflux ◽  
Peptic Ulcer Disease ◽  
Reflux Disease ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Ulcer Disease ◽  
H Pylori

Background: Proton pump inhibitors (PPIs) are one of the most commonly used classes of drugs. Though, the quantum clinical benefit of newer and more expensive PPIs over the older generation PPIs residues undefined. The present meta-analysis ought to assess the safety and clinical profiles of esomeprazole versus omeprazole at pharmacologically equivalent doses in healing gastroesophageal reflux disease (GERD), peptic ulcer disease and eradicating Helicobacter pylori infection.Methods: PubMed and the Cochrane Library were searched for randomized controlled trials comparing esomeprazole with omeprazole at all doses up to July 2017. Meta-analysis was conducted using a random effects model, and heterogeneity in the estimated effects was investigated using meta-regression.Results: Eleven trials were included and none of which compared esomeprazole with omeprazole in peptic ulcer disease. In gastroesophageal reflux disease, esomeprazole 40 mg (relative risk (RR) = 1.11; 95% confidence interval (CI) 1.14 to 1.23) and 20 mg (RR=1.08; 95% CI 1.02 to 1.12) significantly improved esophagitis healing when compared with omeprazole 20 mg at week 8. In H. pylori eradication, there was no difference in the treatment effects between esomeprazole 20 mg and omeprazole 20 mg (RR = 1.05;95% CI 1.01 to 1.11).Conclusions: Esomeprazole established better esophagitis healing rate in patients with GERD than omeprazole at week 8. Though, this clinical advantage reduced when both drugs were given at the same doses at week 4. Superiority of esomeprazole was not perceived in the H. pylori eradication rates.

scholarly journals Should We Test for Helicobacter Pylori before Treating Gastroesophageal Reflux Disease?

2005 ◽  
Vol 19 (7) ◽  
pp. 425-427 ◽  
Author(s):  
Paul Moayyedi
Keyword(s):  
Helicobacter Pylori ◽  
Gastroesophageal Reflux Disease ◽  
Gastroesophageal Reflux ◽  
Randomized Controlled Trials ◽  
Chronic Gastritis ◽  
Reflux Disease ◽  
Developed Countries ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
H Pylori

Gastroesophageal reflux disease (GERD) is a common problem in childhood. The cause is uncertain but because the incidence of GERD is increasing in developed countries and the prevalence of Helicobacter pylori is decreasing, it has been suggested that this infection protects against GERD. Observational data from 95 children, however, suggest that H pylori eradication does not have a deleterious effect on GERD and this is supported by randomized controlled trials in adults. H pylori eradication may also reduce the efficacy of proton pump inhibitor therapy in infected patients. There are no data from children but inferences from randomized controlled trials in adults suggest this effect is likely to be modest and of uncertain clinical significance. H pylori is an important risk factor for distal gastric adenocarcinoma. It is likely that treating the infection in childhood will prevent pre-malignant changes associated with H pylori from developing in the future. A meta-analysis of four randomized controlled trials suggest that there is a statistically significant impact on healing of chronic gastritis after one year compared with placebo (RR of chronic gastritis: 0.27; 95% CI 0.23 to 0.32). H pylori eradication is therefore recommended in children with GERD that are having an endoscopy. However, when the diagnosis of GERD is being made clinically or by pH monitoring, it is not necessary to screen for H pylori.

scholarly journals Helicobacter pylori infection reduces the risk of gastroesophageal reflux disease

2021 ◽  
pp. 96-101
Author(s):  
R. I. Khlynova ◽  
O. M. Khromtsova ◽  
R. B. Berdnikov ◽  
I. B. Khlynov
Keyword(s):  
Helicobacter Pylori ◽  
Gastroesophageal Reflux Disease ◽  
Gastric Mucosa ◽  
Gastroesophageal Reflux ◽  
Observational Study ◽  
Reflux Disease ◽  
Helicobacter Pylori Infection ◽  
Cross Sectional ◽  
Biopsy Specimens ◽  
H Pylori

The aim is to study the effect of Helicobacter pylori infection on risk of developing gastroesophageal reflux disease. Materials and methods - cross-sectional observational study of 1007 patients with dyspepsia syndrome who underwent videoesophagogastroduodenoscopy with biopsy and histological examination of biopsy specimens of the gastric mucosa by OLGA-system. The age, gender, overweight, cigarette smoking, presence of Helicobacter pylori infection and gastritis stage were assessed. Results - the study showed a significant decrease in the incidence of gastroesophageal reflux disease in patients with positive H. Pylori status by 4% (RR 0,68; 95% CI, 0.49-0.94, p=0,041). The risk of developing gastroesophageal reflux disease significantly higher in overweight (RR 2,62; 95% CI 2,0-3,56; р<0,001) men (RR 1,76; 95% CI 1,33-2,32; р=0,0046) who smoked cigarettes (RR 3,23; 95% CI 2,45-4,24; р<0,001) and was not associated with the patient’s age and the stage of gastritis (р>0,05). Conclusion - a significant reduction in the frequency and risk of developing gastroesophageal reflux disease in patients with Helicobacter pylori infection is demonstrated.

Sign in / Sign up

Export Citation Format

Share Document